{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:32Z","timestamp":1792013132796,"version":"4.4.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K23GM117309"],"award-info":[{"award-number":["K23GM117309"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00403-019-01972-3","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T17:41:41Z","timestamp":1567791701000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets"],"prefix":"10.1007","volume":"312","author":[{"given":"Julie K.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mamalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7619-7650","authenticated-orcid":false,"given":"Jared","family":"Jagdeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"1972_CR1","doi-asserted-by":"publisher","first-page":"e000260","DOI":"10.1136\/rmdopen-2016-000260","volume":"2","author":"Y Allanore","year":"2016","unstructured":"Allanore Y, Matucci-Cerinic M, Distler O (2016) Treatment of systemic sclerosis: is there any hope for the future? RMD Open 2:e000260","journal-title":"RMD Open"},{"key":"1972_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.ppat.1002003","volume":"7","author":"JE Allen","year":"2011","unstructured":"Allen JE, Wynn TA (2011) Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 7:5\u20138","journal-title":"PLoS Pathog"},{"key":"1972_CR3","unstructured":"Altair Therapeutics. Study evaluating the effects of AIR645 on allergen-induced airway responses in subjects with mild atopic asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00941577. Accessed 10 Nov 2018"},{"key":"1972_CR4","first-page":"65","volume":"6","author":"CM Artlett","year":"2014","unstructured":"Artlett CM (2014) Animal models of systemic sclerosis: their utility and limitations. Open Access Rheumatol Res Rev 6:65\u201381","journal-title":"Open Access Rheumatol Res Rev"},{"key":"1972_CR5","unstructured":"AstraZeneca (2018) Clinical trials appendix Q1 2018 results update. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2018\/Q1-2018\/Q1 2018 Clinical trials appendix.pdf. Accessed 10 Nov 2018"},{"key":"1972_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM et al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA 315:469","journal-title":"JAMA"},{"key":"1972_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000447692","volume":"170","author":"D Bagnasco","year":"2016","unstructured":"Bagnasco D, Ferrando M, Varricchi G et al (2016) A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol 170:122\u2013131","journal-title":"Int Arch Allergy Immunol"},{"key":"1972_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/bmj.326.7380.88","volume":"326","author":"A Bayat","year":"2003","unstructured":"Bayat A, McGrouther D, Ferguson M (2003) Skin scarring. BMJ 326:88\u201392","journal-title":"BMJ"},{"key":"1972_CR9","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1002\/art.27647","volume":"62","author":"C Beyer","year":"2010","unstructured":"Beyer C, Schett G, Distler O, Distler JHW (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62:2831\u20132844","journal-title":"Arthritis Rheum"},{"key":"1972_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s10875-005-7827-3","volume":"25","author":"RK Bhogal","year":"2005","unstructured":"Bhogal RK, Stoica CM, McGaha TL, Bona CA (2005) Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol 25:592\u2013603","journal-title":"J Clin Immunol"},{"key":"1972_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-006-0651-7","volume":"297","author":"O Bock","year":"2006","unstructured":"Bock O, Schmid-Ott G, Malewski P, Mrowietz U (2006) Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 297:433\u2013438","journal-title":"Arch Dermatol Res"},{"key":"1972_CR12","doi-asserted-by":"publisher","first-page":"989.e4","DOI":"10.1016\/j.jaci.2014.01.002","volume":"133","author":"EH De Boever","year":"2014","unstructured":"De Boever EH, Ashman C, Cahn AP et al (2014) Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 133:989.e4\u2013996.e4","journal-title":"J Allergy Clin Immunol"},{"key":"1972_CR13","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","volume":"160","author":"LC Borish","year":"1999","unstructured":"Borish LC, Nelson HS, Lanz MJ et al (1999) Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160:1816\u20131823","journal-title":"Am J Respir Crit Care Med"},{"key":"1972_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbadis.2012.09.014","volume":"1832","author":"LA Borthwick","year":"2013","unstructured":"Borthwick LA, Wynn TA, Fisher AJ (2013) Cytokine mediated tissue fibrosis. Biochim Biophys Acta Mol Basis Dis 1832:1049\u20131060","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1972_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bjps.2008.03.020","volume":"61","author":"BC Brown","year":"2008","unstructured":"Brown BC, McKenna SP, Siddhi K et al (2008) The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthetic Surg 61:1049\u20131058","journal-title":"J Plast Reconstr Aesthetic Surg"},{"key":"1972_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2047-1440-2-16","volume":"2","author":"SM Brunner","year":"2013","unstructured":"Brunner SM, Schiechl G, Kesselring R et al (2013) IL-13 signaling via IL-13R\u03b12 triggers TGF-\u03b21-dependent allograft fibrosis. Transplant Res 2:16","journal-title":"Transplant Res"},{"key":"1972_CR17","doi-asserted-by":"publisher","first-page":"s32","DOI":"10.1111\/j.1524-475X.2010.00607.x","volume":"19","author":"JA Bush","year":"2011","unstructured":"Bush JA, McGrouther DA, Young VL et al (2011) Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies. Wound Repair Regen 19:s32\u2013s37","journal-title":"Wound Repair Regen"},{"key":"1972_CR18","first-page":"601","volume":"13","author":"MC Catley","year":"2010","unstructured":"Catley MC (2010) Asthma and COPD\u2013IQPC\u2019s second conference. IDrugs 13:601\u2013604","journal-title":"IDrugs"},{"key":"1972_CR19","doi-asserted-by":"publisher","first-page":"452.e9","DOI":"10.1016\/j.jaci.2015.08.046","volume":"137","author":"AM Chaker","year":"2016","unstructured":"Chaker AM, Shamji MH, Dumitru FA et al (2016) Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. J Allergy Clin Immunol 137:452.e9\u2013461.e9","journal-title":"J Allergy Clin Immunol"},{"key":"1972_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1084\/jem.20020903","volume":"197","author":"MG Chiaramonte","year":"2003","unstructured":"Chiaramonte MG, Mentink-Kane M, Jacobson BA et al (2003) Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 197:687\u2013701","journal-title":"J Exp Med"},{"key":"1972_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08830189809084486","volume":"17","author":"P Chomarat","year":"1998","unstructured":"Chomarat P, Banchereau J (1998) Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 17:1\u201352","journal-title":"Int Rev Immunol"},{"key":"1972_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.200909-1448OC","volume":"181","author":"J Corren","year":"2010","unstructured":"Corren J, Busse W, Meltzer EO et al (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181:788\u2013796","journal-title":"Am J Respir Crit Care Med"},{"key":"1972_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","volume":"64","author":"S Danese","year":"2015","unstructured":"Danese S, Rudzi\u0144ski J, Brandt W et al (2015) Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64:243\u2013249","journal-title":"Gut"},{"key":"1972_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00018-015-2110-0","volume":"73","author":"IA Darby","year":"2016","unstructured":"Darby IA, Zakuan N, Billet F, Desmouli\u00e8re A (2016) The myofibroblast, a key cell in normal and pathological tissue repair. Cell Mol Life Sci 73:1145\u20131157","journal-title":"Cell Mol Life Sci"},{"key":"1972_CR25","first-page":"301","volume":"7","author":"IA Darby","year":"2014","unstructured":"Darby IA, Laverdet B, Bont\u00e9 F, Desmouli\u00e8re A (2014) Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol 7:301\u2013311","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1972_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.autrev.2003.10.003","volume":"3","author":"CP Denton","year":"2004","unstructured":"Denton CP, Abraham DJ (2004) Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun Rev 3:285\u2013293","journal-title":"Autoimmun Rev"},{"key":"1972_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1046\/j.1523-1747.2002.01753.x","volume":"118","author":"A Elbe-B\u00fcrger","year":"2002","unstructured":"Elbe-B\u00fcrger A, Egyed A, Olt S et al (2002) Overexpression of IL-4 alters the homeostasis in the skin. J Investig Dermatol 118:767\u2013778","journal-title":"J Investig Dermatol"},{"key":"1972_CR28","first-page":"823","volume":"37","author":"C Fertin","year":"1991","unstructured":"Fertin C, Nicolas JF, Gillery P et al (1991) Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol 37:823\u2013829","journal-title":"Cell Mol Biol"},{"key":"1972_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm1332","volume":"12","author":"S Fichtner-Feigl","year":"2006","unstructured":"Fichtner-Feigl S, Strober W, Kawakami K et al (2006) IL-13 signaling through the IL-13\u03b12 receptor is involved in induction of TGF-\u03b21 production and fibrosis. Nat Med 12:99\u2013106","journal-title":"Nat Med"},{"key":"1972_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","volume":"56","author":"P Fuschiotti","year":"2011","unstructured":"Fuschiotti P (2011) Role of IL-13 in systemic sclerosis. Cytokine 56:544\u2013549","journal-title":"Cytokine"},{"key":"1972_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/art.37706","volume":"65","author":"P Fuschiotti","year":"2013","unstructured":"Fuschiotti P, Larregina AT, Ho J et al (2013) Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 65:236\u2013246","journal-title":"Arthritis Rheum"},{"key":"1972_CR32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/art.24432","volume":"60","author":"P Fuschiotti","year":"2009","unstructured":"Fuschiotti P, Medsger TAJ, Morel PA (2009) Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 60:1119\u20131128","journal-title":"Arthritis Rheum"},{"key":"1972_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH (2017) Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 13:425\u2013437","journal-title":"Expert Rev Clin Immunol"},{"key":"1972_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nri3476","volume":"13","author":"WC Gause","year":"2013","unstructured":"Gause WC, Wynn TA, Allen JE (2013) Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 13:607\u2013614","journal-title":"Nat Rev Immunol"},{"key":"1972_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1164\/rccm.201008-1210OC","volume":"183","author":"GM Gauvreau","year":"2011","unstructured":"Gauvreau GM, Boulet L-P, Cockcroft DW et al (2011) Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 183:1007\u20131014","journal-title":"Am J Respir Crit Care Med"},{"key":"1972_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","volume":"18","author":"RL Gieseck","year":"2018","unstructured":"Gieseck RL, Wilson MS, Wynn TA (2018) Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol 18:62\u201376","journal-title":"Nat Rev Immunol"},{"key":"1972_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0014-5793(92)80448-P","volume":"302","author":"P Gillery","year":"1992","unstructured":"Gillery P, Fertin C, Nicolas JF et al (1992) Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 302:231\u2013234","journal-title":"FEBS Lett"},{"key":"1972_CR38","first-page":"817","volume":"40","author":"MH Gold","year":"2014","unstructured":"Gold MH, Berman B, Clementoni MT et al (2014) Updated international clinical recommendations on scar management: part 1\u2014evaluating the evidence. Dermatol Surg 40:817\u2013824","journal-title":"Dermatol Surg"},{"key":"1972_CR39","first-page":"825","volume":"40","author":"MH Gold","year":"2014","unstructured":"Gold MH, McGuire M, Mustoe TA et al (2014) Updated international clinical recommendations on scar management: part 2\u2014algorithms for scar prevention and treatment. Dermatol Surg 40:825\u2013831","journal-title":"Dermatol Surg"},{"key":"1972_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","volume":"15","author":"MB Greenblatt","year":"2013","unstructured":"Greenblatt MB, Aliprantis AO (2013) The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep 15:297","journal-title":"Curr Rheumatol Rep"},{"key":"1972_CR41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ajpath.2011.11.024","volume":"180","author":"MB Greenblatt","year":"2012","unstructured":"Greenblatt MB, Sargent JL, Farina G et al (2012) Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 180:1080\u20131094","journal-title":"Am J Pathol"},{"key":"1972_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nature07039","volume":"453","author":"GC Gurtner","year":"2008","unstructured":"Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453:314\u2013321","journal-title":"Nature"},{"key":"1972_CR43","unstructured":"Guttman E (2018) A pilot study of tralokinumab in subjects with moderate to severe alopecia areata. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684097. Accessed 10 Nov 2018"},{"key":"1972_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","volume":"4","author":"NA Hanania","year":"2016","unstructured":"Hanania NA, Korenblat P, Chapman KR et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781\u2013796","journal-title":"Lancet Respir Med"},{"key":"1972_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania NA, Noonan M, Corren J et al (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:748\u2013756","journal-title":"Thorax"},{"key":"1972_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2249.2002.01973.x","volume":"130","author":"TK Hart","year":"2002","unstructured":"Hart TK, Blackburn MN, Brigham-Burke M et al (2002) Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130:93\u2013100","journal-title":"Clin Exp Immunol"},{"key":"1972_CR47","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328\u2013332","journal-title":"J Rheumatol"},{"key":"1972_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000071783","volume":"207","author":"M Hasegawa","year":"2003","unstructured":"Hasegawa M, Sato S, Nagaoka T et al (2003) Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 207:141\u2013147","journal-title":"Dermatology"},{"key":"1972_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40139-015-0077-z","volume":"3","author":"W He","year":"2015","unstructured":"He W, Dai C (2015) Key fibrogenic signaling. Curr Pathobiol Rep 3:183\u2013192","journal-title":"Curr Pathobiol Rep"},{"issue":"3","key":"1972_CR50","doi-asserted-by":"publisher","first-page":"592-603.e10","DOI":"10.1053\/j.gastro.2018.10.051","volume":"156","author":"Ikuo Hirano","year":"2019","unstructured":"Hirano I, Collins MH, Assouline-Dayan Y et al (2019) RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology 156:592\u2013603.e10","journal-title":"Gastroenterology"},{"key":"1972_CR51","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1096\/fj.01-0306fje","volume":"15","author":"KF Hoffmann","year":"2001","unstructured":"Hoffmann KF, McCarty TC, Segal DH et al (2001) Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J 15:2545\u20132547","journal-title":"FASEB J"},{"key":"1972_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bcp.12589","volume":"80","author":"F Hua","year":"2015","unstructured":"Hua F, Ribbing J, Reinisch W et al (2015) A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharmacol 80:101\u2013109","journal-title":"Br J Clin Pharmacol"},{"key":"1972_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00011-015-0806-0","volume":"64","author":"X-L Huang","year":"2015","unstructured":"Huang X-L, Wang Y-J, Yan J-W et al (2015) Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res 64:151\u2013159","journal-title":"Inflamm Res"},{"key":"1972_CR54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-#","volume":"44","author":"H Ihn","year":"2001","unstructured":"Ihn H, Yamane K, Kubo M, Tamaki K (2001) Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 44:474\u2013480","journal-title":"Arthritis Rheum"},{"key":"1972_CR55","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jamadermatol.2016.5232","volume":"153","author":"J Jagdeo","year":"2017","unstructured":"Jagdeo J, Shumaker PR (2017) Traumatic scarring. JAMA Dermatol 153:364","journal-title":"JAMA Dermatol"},{"key":"1972_CR56","doi-asserted-by":"publisher","first-page":"41783","DOI":"10.1074\/jbc.M406951200","volume":"279","author":"M Jinnin","year":"2004","unstructured":"Jinnin M, Ihn H, Yamane K, Tamaki K (2004) Interleukin-13 stimulates the transcription of the human 2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279:41783\u201341791","journal-title":"J Biol Chem"},{"key":"1972_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11882-018-0804-8","volume":"18","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF (2018) Biologics and small molecule agents in allergic and immunologic skin diseases. Curr Allergy Asthma Rep 18:55","journal-title":"Curr Allergy Asthma Rep"},{"key":"1972_CR58","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4049\/jimmunol.173.6.4020","volume":"173","author":"M Kaviratne","year":"2004","unstructured":"Kaviratne M, Hesse M, Leusink M et al (2004) IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 173:4020\u20134029","journal-title":"J Immunol"},{"key":"1972_CR59","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.immuni.2015.09.005","volume":"43","author":"JA Knipper","year":"2015","unstructured":"Knipper JA, Willenborg S, Brinckmann J et al (2015) Interleukin-4 receptor \u03b1 signaling in myeloid cells controls collagen fibril assembly in skin repair. Immunity 43:803\u2013816","journal-title":"Immunity"},{"key":"1972_CR60","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1073\/pnas.052709999","volume":"99","author":"T Kodera","year":"2002","unstructured":"Kodera T, McGaha TL, Phelps R et al (2002) Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 99:3800\u20133805","journal-title":"Proc Natl Acad Sci USA"},{"key":"1972_CR61","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1007\/s00018-016-2268-0","volume":"73","author":"NX Land\u00e9n","year":"2016","unstructured":"Land\u00e9n NX, Li D, St\u00e5hle M (2016) Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci 73:3861\u20133885","journal-title":"Cell Mol Life Sci"},{"key":"1972_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00454","volume":"8","author":"P Laurent","year":"2017","unstructured":"Laurent P, Jolivel V, Manicki P et al (2017) Immune-mediated repair: a matter of plasticity. Front Immunol 8:1\u20138","journal-title":"Front Immunol"},{"key":"1972_CR63","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.anai.2018.01.009","volume":"120","author":"MG Lawrence","year":"2018","unstructured":"Lawrence MG, Steinke JW, Borish L (2018) Cytokine-targeting biologics for allergic diseases. Ann Allergy Asthma Immunol 120:376\u2013381","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1972_CR64","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask A, Abraham DJ (2004) TGF-\u03b2 signaling and the fibrotic response. FASEB J 18:816\u2013827","journal-title":"FASEB J"},{"key":"1972_CR65","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1084\/jem.194.6.809","volume":"194","author":"CG Lee","year":"2001","unstructured":"Lee CG, Homer RJ, Zhu Z et al (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor \u03b21. J Exp Med 194:809\u2013821","journal-title":"J Exp Med"},{"key":"1972_CR66","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/ijms19030711","volume":"19","author":"H Lee","year":"2018","unstructured":"Lee H, Jang Y (2018) Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci 19:711","journal-title":"Int J Mol Sci"},{"key":"1972_CR67","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/0923-1811(95)00469-6","volume":"12","author":"KS Lee","year":"1996","unstructured":"Lee KS, Ro YJ, Ryoo YW et al (1996) Regulation of interleukin-4 on collagen gene expression by systemic sclerosis fibroblasts in culture. J Dermatol Sci 12:110\u2013117","journal-title":"J Dermatol Sci"},{"key":"1972_CR68","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","volume":"3","author":"F Legrand","year":"2015","unstructured":"Legrand F, Klion AD (2015) Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 3:167\u2013174","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1972_CR69","unstructured":"LEO Pharma. Tralokinumab monotherapy for moderate to severe atopic dermatitis\u2014ECZTRA 1 (ECZema TRAlokinumab trial no. 1) (ECZTRA 1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131648. Accessed 10 Nov 2018"},{"key":"1972_CR70","unstructured":"LEO Pharma. Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials\u2014ECZTEND. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03587805. Accessed 10 Nov 2018"},{"key":"1972_CR71","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.kint.2017.04.021","volume":"92","author":"H Liang","year":"2017","unstructured":"Liang H, Zhang Z, Yan J et al (2017) The IL-4 receptor \u03b1 has a critical role in bone marrow-derived fibroblast activation and renal fibrosis. Kidney Int 92:1433\u20131443","journal-title":"Kidney Int"},{"key":"1972_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/wrr.12398","volume":"24","author":"MK Lichtman","year":"2016","unstructured":"Lichtman MK, Otero-Vinas M, Falanga V (2016) Transforming growth factor beta (TGF-\u03b2) isoforms in wound healing and fibrosis. Wound Repair Regen 24:215\u2013222","journal-title":"Wound Repair Regen"},{"key":"1972_CR73","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1126\/sciimmunol.aat1604","volume":"3","author":"CM Lloyd","year":"2018","unstructured":"Lloyd CM, Snelgrove RJ (2018) Type 2 immunity: expanding our view. Sci Immunol 3:1604","journal-title":"Sci Immunol"},{"key":"1972_CR74","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.4049\/jimmunol.179.6.3926","volume":"179","author":"P Loke","year":"2007","unstructured":"Loke P, Gallagher I, Nair MG et al (2007) Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 179:3926\u20133936","journal-title":"J Immunol"},{"key":"1972_CR75","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/CMR.9.4.532","volume":"9","author":"DR Lucey","year":"1996","unstructured":"Lucey DR, Clerici M, Shearer GM (1996) Type 1, and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9:532\u2013562","journal-title":"Clin Microbiol Rev"},{"key":"1972_CR76","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/978-1-84800-165-7_41","volume-title":"Clinical and basic immunodermatology","author":"IG Luzina","year":"2008","unstructured":"Luzina IG, Atamas SP (2008) Fibrotic skin diseases. In: Gaspari A, Tyring S (eds) Clinical and basic immunodermatology. Springer, London, pp 721\u2013737"},{"key":"1972_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0106-13","volume":"12","author":"TT MacDonald","year":"2006","unstructured":"MacDonald TT (2006) Decoy receptor springs to life and eases fibrosis. Nat Med 12:13\u201314","journal-title":"Nat Med"},{"key":"1972_CR78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1165\/rcmb.2012-0080TR","volume":"47","author":"T Maes","year":"2012","unstructured":"Maes T, Joos GF, Brusselle GG (2012) Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol 47:261\u2013270","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1972_CR79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/wound.2016.0696","volume":"7","author":"CD Marshall","year":"2018","unstructured":"Marshall CD, Hu MS, Leavitt T et al (2018) Cutaneous scarring: basic science, current treatments, and future directions. Adv Wound Care 7:29\u201345","journal-title":"Adv Wound Care"},{"key":"1972_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","volume":"75","author":"RD May","year":"2015","unstructured":"May RD, Fung M (2015) Strategies targeting the IL-4\/IL-13 axes in disease. Cytokine 75:89\u2013116","journal-title":"Cytokine"},{"key":"1972_CR81","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.163.10.5693","volume":"163","author":"LL McCormick","year":"1999","unstructured":"McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163:5693\u20135699","journal-title":"J Immunol"},{"key":"1972_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","volume":"75","author":"SM McCormick","year":"2015","unstructured":"McCormick SM, Heller NM (2015) Commentary: iL-4 and IL-13 receptors and signaling. Cytokine 75:38\u201350","journal-title":"Cytokine"},{"key":"1972_CR83","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1523-1747.2001.00217.x","volume":"116","author":"T McGaha","year":"2001","unstructured":"McGaha T, Saito S, Phelps RG et al (2001) Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Investig Dermatol 116:136\u2013143","journal-title":"J Investig Dermatol"},{"key":"1972_CR84","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1002\/art.11089","volume":"48","author":"TL McGaha","year":"2003","unstructured":"McGaha TL, Le M, Kodera T et al (2003) Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 48:2275\u20132284","journal-title":"Arthritis Rheum"},{"key":"1972_CR85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1568-9972(02)00027-7","volume":"1","author":"TL McGaha","year":"2002","unstructured":"McGaha TL, Bona CA (2002) Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev 1:174\u2013181","journal-title":"Autoimmun Rev"},{"key":"1972_CR86","unstructured":"Memorial Sloan Kettering Cancer Center. Immunotherapy for the treatment of breast cancer related upper extremity lymphedema (BCRL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02494206. Accessed 10 Nov 2018"},{"key":"1972_CR87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol 12:325\u2013338","journal-title":"Nat Rev Nephrol"},{"key":"1972_CR88","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1172\/JCI5504","volume":"103","author":"A Le Moine","year":"1999","unstructured":"Le Moine A, Flamand V, Demoor FX et al (1999) Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Investig 103:1659\u20131667","journal-title":"J Clin Investig"},{"key":"1972_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2017.00083","volume":"4","author":"ZB Mokos","year":"2017","unstructured":"Mokos ZB, Jovi\u0107 A, Grgurevi\u0107 L et al (2017) Current therapeutic approach to hypertrophic scars. Front Med 4:1\u201311","journal-title":"Front Med"},{"key":"1972_CR90","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.1780350111","volume":"35","author":"BW Needleman","year":"1992","unstructured":"Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35:67\u201372","journal-title":"Arthritis Rheum"},{"key":"1972_CR91","doi-asserted-by":"publisher","first-page":"800.e9","DOI":"10.1016\/j.jaci.2011.05.013","volume":"128","author":"GC Nicholson","year":"2011","unstructured":"Nicholson GC, Kariyawasam HH, Tan AJ et al (2011) The effects of an anti\u2013IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J Allergy Clin Immunol 128:800.e9\u2013807.e9","journal-title":"J Allergy Clin Immunol"},{"key":"1972_CR92","unstructured":"Novartis Pharmaceuticals. A phase II efficacy study in fistulizing Crohn\u2019s disease patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01355614. Accessed 10 Nov 2018"},{"key":"1972_CR93","unstructured":"Novartis Pharmaceuticals. Safety and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis (IPF). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01266135. Accessed 10 Nov 2018"},{"key":"1972_CR94","unstructured":"Novartis Pharmaceuticals. Efficacy 2 part study of identification of keloid biomarkers and effect of QAX576 on keloid recurrence. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00987545. Accessed 10 Nov 2018"},{"key":"1972_CR95","unstructured":"Novartis Pharmaceuticals. QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00581997. Accessed 10 Nov 2018"},{"key":"1972_CR96","unstructured":"Novartis Pharmaceuticals. A study to establish the efficacy of QBX258 in patients with moderate to severe asthma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01479595. Accessed 10 Nov 2018"},{"key":"1972_CR97","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/biof.1117","volume":"39","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S (2013) Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors 39:593\u2013596","journal-title":"Biofactors"},{"key":"1972_CR98","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1006\/cimm.1999.1537","volume":"196","author":"CJ Ong","year":"1999","unstructured":"Ong CJ, Ip S, Teh SJ et al (1999) A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 196:60\u201368","journal-title":"Cell Immunol"},{"key":"1972_CR99","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2619::AID-IMMU2619>3.0.CO;2-M","volume":"28","author":"C Ong","year":"1998","unstructured":"Ong C, Wong C, Roberts CR et al (1998) Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 28:2619\u20132629","journal-title":"Eur J Immunol"},{"key":"1972_CR100","first-page":"988","volume":"292","author":"A Oriente","year":"2000","unstructured":"Oriente A, Fedarko NS, Pacocha SE et al (2000) Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292:988\u2013994","journal-title":"J Pharmacol Exp Ther"},{"key":"1972_CR101","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","volume":"6","author":"RA Panettieri","year":"2018","unstructured":"Panettieri RA, Sj\u00f6bring U, P\u00e9terffy A et al (2018) Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med 6:511\u2013525","journal-title":"Lancet Respir Med"},{"key":"1972_CR102","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1164\/rccm.201704-0784OC","volume":"197","author":"JM Parker","year":"2018","unstructured":"Parker JM, Glaspole IN, Lancaster LH et al (2018) A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 197:94\u2013103","journal-title":"Am J Respir Crit Care Med"},{"key":"1972_CR103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-84800-165-7_1","volume-title":"Clinical and basic immunodermatology","author":"OA Perez","year":"2008","unstructured":"Perez OA, Berman B (2008) Cytokines and chemokines. In: Gaspari A, Tyring S (eds) Clinical and basic immunodermatology. Springer, London, pp 3\u201316"},{"key":"1972_CR104","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI116015","volume":"90","author":"A Postlethwaite","year":"1992","unstructured":"Postlethwaite A, Holness MA, Katai M, Raghow R (1992) Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Investig 90:1479\u20131485","journal-title":"J Clin Investig"},{"key":"1972_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2011.05.055","volume":"66","author":"C Profyris","year":"2012","unstructured":"Profyris C, Tziotzios C, Do Vale I (2012) Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics part I. The molecular basis of scar formation. J Am Acad Dermatol 66:1\u201310","journal-title":"J Am Acad Dermatol"},{"key":"1972_CR106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.arbres.2014.02.002","volume":"50","author":"S Quirce","year":"2014","unstructured":"Quirce S, Bobolea I, Dom\u00ednguez-Ortega J, Barranco P (2014) Future biologic therapies in asthma. Arch Bronconeumol 50:355\u2013361","journal-title":"Arch Bronconeumol"},{"key":"1972_CR107","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475\u20132485","journal-title":"N Engl J Med"},{"issue":"6","key":"1972_CR108","doi-asserted-by":"publisher","first-page":"1801130","DOI":"10.1183\/13993003.01130-2018","volume":"52","author":"Ganesh Raghu","year":"2018","unstructured":"Raghu G, Richeldi L, Crestani B et al (2018) SAR156597 in idiopathic pulmonary fibrosis: a phase 2, placebo-controlled study (DRI11772). Eur Respir J 52:1801130","journal-title":"European Respiratory Journal"},{"key":"1972_CR109","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.0903306","volume":"184","author":"AL Rankin","year":"2010","unstructured":"Rankin AL, Mumm JB, Murphy E et al (2010) IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184:1526\u20131535","journal-title":"J Immunol"},{"key":"1972_CR110","unstructured":"Regeneron Pharmaceuticals. Dupilumab as an adjunct for subcutaneous grass immunotherapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03558997. Accessed 10 Nov 2018"},{"key":"1972_CR111","unstructured":"Regeneron Pharmaceuticals. Study to Determine the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis (EoE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633617. Accessed 10 Nov 2018"},{"key":"1972_CR112","unstructured":"Regeneron Pharmaceuticals FDA Approves asthma indication for Dupixent\u00ae (dupilumab). https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-asthma-indication-dupixentr-dupilumab. Accessed 10 Nov 2018"},{"key":"1972_CR113","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","volume":"64","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Pan\u00e9s J, Khurana S et al (2015) Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 64:894\u2013900","journal-title":"Gut"},{"key":"1972_CR114","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2017) The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther 34:1594\u20131609","journal-title":"Adv Ther"},{"key":"1972_CR115","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/ACI.0000000000000553","volume":"19","author":"LM Roesner","year":"2019","unstructured":"Roesner LM, Zeitvogel J, Heratizadeh A (2019) Common and different roles of IL-4 and IL-13 in skin allergy and clinical implications. Curr Opin Allergy Clin Immunol 19:319\u2013327","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1972_CR116","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A et al (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135:500\u2013507","journal-title":"J Allergy Clin Immunol"},{"key":"1972_CR117","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archderm.1996.03890310088013","volume":"132","author":"V Salmon-Ehr","year":"1996","unstructured":"Salmon-Ehr V, Serpier H, Nawrocki B et al (1996) Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132:802\u2013806","journal-title":"Arch Dermatol"},{"key":"1972_CR118","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/labinvest.3780141","volume":"80","author":"V Salmon-Ehr","year":"2000","unstructured":"Salmon-Ehr V, Ramont L, Godeau G et al (2000) Implication of interleukin-4 in wound healing. Lab Investig 80:1337\u20131343","journal-title":"Lab Investig"},{"key":"1972_CR119","unstructured":"Sanofi. Effectiveness and safety of SAR156597 in treating diffuse systemic sclerosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02921971. Accessed 10 Nov 2018"},{"key":"1972_CR120","unstructured":"Sanofi. A controlled clinical study of dupilumab in patients with nasal polyps (SINUS-24). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02912468. Accessed 10 Nov 2018"},{"key":"1972_CR121","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1524-475X.2009.00543.x","volume":"17","author":"CK Sen","year":"2010","unstructured":"Sen CK, Gordillo GM, Roy S et al (2010) Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 17:763\u2013771","journal-title":"Wound Repair Regen"},{"key":"1972_CR122","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1242\/jcs.107.5.1137","volume":"107","author":"M Shah","year":"1994","unstructured":"Shah M, Foreman DM, Ferguson MW (1994) Neutralising antibody to TGF-beta 1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci 107:1137\u20131157","journal-title":"J Cell Sci"},{"key":"1972_CR123","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1242\/jcs.108.3.985","volume":"108","author":"M Shah","year":"1995","unstructured":"Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108:985\u20131002","journal-title":"J Cell Sci"},{"key":"1972_CR124","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M (2017) Dupilumab: first global approval. Drugs 77:1115\u20131121","journal-title":"Drugs"},{"key":"1972_CR125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1468-3083.2011.04200.x","volume":"26","author":"GP Sidgwick","year":"2012","unstructured":"Sidgwick GP, Bayat A (2012) Extracellular matrix molecules implicated in hypertrophic and keloid scarring. J Eur Acad Dermatol Venereol 26:141\u2013152","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1972_CR126","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"key":"1972_CR127","doi-asserted-by":"publisher","first-page":"863.e11","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF et al (2018) Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863.e11\u2013871.e11","journal-title":"J Am Acad Dermatol"},{"key":"1972_CR128","unstructured":"Swigris J, Ogura T, Scholand M et al, The RIFF Study (2018) (Cohort A): a phase II, randomized, double-blind, placebo-controlled trial of lebrikizumab as monotherapy in patients with idiopathic pulmonary fibrosis (abstract A6167). American Thoracic Society 2018 International Conference, San Diego, CA, USA, 2018"},{"key":"1972_CR129","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11882-016-0650-5","volume":"16","author":"H-TT Tan","year":"2016","unstructured":"Tan H-TT, Sugita K, Akdis CA (2016) Novel biologicals for the treatment of allergic diseases and asthma. Curr Allergy Asthma Rep 16:70","journal-title":"Curr Allergy Asthma Rep"},{"key":"1972_CR130","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40257-016-0175-7","volume":"17","author":"AP Trace","year":"2016","unstructured":"Trace AP, Enos CW, Mantel A, Harvey VM (2016) Keloids and hypertrophic scars: a spectrum of clinical challenges. Am J Clin Dermatol 17:201\u2013223","journal-title":"Am J Clin Dermatol"},{"key":"1972_CR131","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/jir.2006.26.179","volume":"26","author":"EE Tredget","year":"2006","unstructured":"Tredget EE, Yang L, Delehanty M et al (2006) Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interf Cytokine Res 26:179\u2013189","journal-title":"J Interf Cytokine Res"},{"key":"1972_CR132","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","volume":"34","author":"CS Tripp","year":"2017","unstructured":"Tripp CS, Cuff C, Campbell AL et al (2017) RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 \u03b11 and \u03b12 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study. Adv Ther 34:1364\u20131381","journal-title":"Adv Ther"},{"key":"1972_CR133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaad.2011.08.035","volume":"66","author":"C Tziotzios","year":"2012","unstructured":"Tziotzios C, Profyris C, Sterling J (2012) Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics: part II. Strategies to reduce scar formation after dermatologic procedures. J Am Acad Dermatol 66:13\u201324","journal-title":"J Am Acad Dermatol"},{"key":"1972_CR134","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archderm.1990.01670290105019","volume":"126","author":"J Uitto","year":"1990","unstructured":"Uitto J (1990) Fibrotic skin diseases. Arch Dermatol 126:661","journal-title":"Arch Dermatol"},{"key":"1972_CR135","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Investig 117:557\u2013567","journal-title":"J Clin Investig"},{"key":"1972_CR136","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/PRS.0000000000000972","volume":"135","author":"GG Walmsley","year":"2015","unstructured":"Walmsley GG, Maan ZN, Wong VW et al (2015) Scarless wound healing: chasing the holy grail. Plast Reconstr Surg 135:907\u2013917","journal-title":"Plast Reconstr Surg"},{"key":"1972_CR137","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/17476348.2018.1520095","volume":"12","author":"GM Walsh","year":"2018","unstructured":"Walsh GM (2018) Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Expert Rev Respir Med 12:957\u2013963","journal-title":"Expert Rev Respir Med"},{"key":"1972_CR138","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fphar.2017.00461","volume":"8","author":"KL Walton","year":"2017","unstructured":"Walton KL, Johnson KE, Harrison CA (2017) Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol 8:461","journal-title":"Front Pharmacol"},{"key":"1972_CR139","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ebiom.2018.01.028","volume":"29","author":"S-Y Weng","year":"2018","unstructured":"Weng S-Y, Wang X, Vijayan S et al (2018) IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal. EBioMedicine 29:92\u2013103","journal-title":"EBioMedicine"},{"key":"1972_CR140","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","volume":"370","author":"S Wenzel","year":"2007","unstructured":"Wenzel S, Wilbraham D, Fuller R et al (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet (London, England) 370:1422\u20131431","journal-title":"Lancet (London, England)"},{"key":"1972_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.1.51.pe55","volume":"1","author":"M Wills-Karp","year":"2008","unstructured":"Wills-Karp M, Finkelman FD (2008) Untangling the complex web of IL-4-and IL-13-mediated signaling pathways. Sci Signal 1:1\u20135","journal-title":"Sci Signal"},{"issue":"1","key":"1972_CR142","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"Andreas Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol 143:135\u2013141","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"1972_CR143","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2009","unstructured":"Wynn TA (2009) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199\u2013210","journal-title":"J Pathol"},{"key":"1972_CR144","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn TA (2015) Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 15:271\u2013282","journal-title":"Nat Rev Immunol"},{"key":"1972_CR145","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA (2004) Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol 4:583\u2013594","journal-title":"Nat Rev Immunol"},{"key":"1972_CR146","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","volume":"21","author":"TA Wynn","year":"2003","unstructured":"Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425\u2013456","journal-title":"Annu Rev Immunol"},{"key":"1972_CR147","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028\u20131040","journal-title":"Nat Med"},{"key":"1972_CR148","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-0030-1255354","volume":"30","author":"T Wynn","year":"2010","unstructured":"Wynn T, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30:245\u2013257","journal-title":"Semin Liver Dis"},{"key":"1972_CR149","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/wrr.12442","volume":"24","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Ding J, Ma Z et al (2016) Systemic depletion of macrophages in the subacute phase of wound healing reduces hypertrophic scar formation. Wound Repair Regen 24:644\u2013656","journal-title":"Wound Repair Regen"},{"key":"1972_CR150","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12079-013-0195-5","volume":"7","author":"Z Zhu","year":"2013","unstructured":"Zhu Z, Ding J, Shankowsky HA, Tredget EE (2013) The molecular mechanism of hypertrophic scar. J Cell Commun Signal 7:239\u2013252","journal-title":"J Cell Commun Signal"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01972-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-019-01972-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01972-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T23:45:57Z","timestamp":1695167157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-019-01972-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s00403-019-01972-3","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no relevant conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}